We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Clinical Trials Begin Using Radiopaque Microscopic Beads

By MedImaging International staff writers
Posted on 17 Oct 2017
Researchers in the US have begun clinical trials of a new experimental cancer treatment that makes use of microscopic beads loaded with a targeted cancer drug, that are visible on a Computed Tomography (CT) scan.

The goal of the Vandetanib-Eluting Radiopaque Beads in Patients with Resectable Liver Malignancies (VEROnA) trial is to evaluate delivering a precisely controlled dose of the drug into the arteries that feed a liver tumor, and to improve treatments for metastatic Colorectal Cancer (mCRC), and primary-liver cancer patients.

The technique was developed by researchers from the University College London Cancer Institute (UCL; London, UK), and BTG (London, UK), a specialist healthcare company, and is intended for treating liver-cancer patients. The technique makes use of microscopic radiopaque beads loaded with a targeted anti-cancer drug called vandetanib, which are placed directly into the liver.

Primary investigator of the study, professor Ricky Sharma, at University College London, said, "The incidence and mortality rates for primary liver cancer continue to climb and it is vital that we explore new treatment approaches. This research is exciting because it is the first time we have been able to pre-load a targeted cancer drug on to an imageable bead, to deliver the targeted drug in high doses to the cancer and see exactly how well the beads reach the target we have defined. By refining the treatment using information from this clinical trial, we may be able to develop a liver-directed treatment as a superior alternative to the rather poorly tolerated drug treatments we currently offer patients with this type of cancer."

Related Links:
University College London Cancer Institute
BTG


Multi-Use Ultrasound Table
Clinton
Portable Color Doppler Ultrasound System
S5000
New
Breast Localization System
MAMMOREP LOOP
Digital Radiographic System
OMNERA 300M

Latest Radiography News

AI Detects Fatty Liver Disease from Chest X-Rays
17 Oct 2017  |   Radiography

AI Detects Hidden Heart Disease in Existing CT Chest Scans
17 Oct 2017  |   Radiography

Ultra-Lightweight AI Model Runs Without GPU to Break Barriers in Lung Cancer Diagnosis
17 Oct 2017  |   Radiography